Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Anaplastic lymphoma kinase (ALK) gene rearrangements are implicated in non-small-cell lung cancer (NSCLC) pathogenesis.
• ALK inhibitors like crizotinib are effective but resistance develops, limiting long-term therapeutic potential.
• Ceritinib represents a potent second-generation ALK inhibitor for ALK-positive NSCLC.

Purpose of the Study:

• To evaluate the safety and efficacy of ceritinib in patients with advanced ALK-rearranged NSCLC.
• To assess ceritinib's activity in patients who have progressed on prior crizotinib treatment.
• To characterize the adverse event profile of ceritinib in this patient population.

Main Methods:

• Phase I clinical trial design.
• Administration of oral ceritinib to patients with ALK-positive tumors.
• Monitoring of antitumor activity and adverse events.

Main Results:

• Ceritinib demonstrated significant antitumor activity in patients with advanced NSCLC.
• Activity was observed in patients who had previously progressed on crizotinib therapy.
• Adverse events were consistent with other ALK tyrosine kinase inhibitors and generally manageable.

Conclusions:

• Ceritinib exhibits promising activity in advanced ALK-rearranged NSCLC, including in crizotinib-resistant cases.
• The safety profile of ceritinib is comparable to existing ALK inhibitors and manageable.
• Ongoing studies are further investigating ceritinib's role in NSCLC treatment algorithms.